Skip to main content

Table 1 Summary of patients being included. Previous treatment (1: yes; 0: no): OP surgery, RTx radiotherapy, AHT anti-hormonal therapy (including second line AHT with bicalutamide, enzalutamide, abiraterone acetate), CTx chemotherapy (docetaxel, cabazitaxel), Ra-223 radium-223 dichloride

From: Influence of dosimetry method on bone lesion absorbed dose estimates in PSMA therapy: application to mCRPC patients receiving Lu-177-PSMA-I&T

Patient Age Activity (GBq) PSA (ng/ml) prior to therapy Gleason score Previous treatment
OP RTx AHT CTx Ra-223
1 61 7.44 25.9 9 0 1 1 1 0
2 75 7.46 38.4 9 1 0 1 1 0
3 75 7.44 1070 8 1 1 1 1 1
4 78 9.04 570 9 0 0 1 1 0
5 62 7.47 848 - 0 1 1 0 0
6 59 7.47 5.38 7b 0 1 1 1 0
7 74 9.19 1696 - 1 1 1 0 0
8 63 7.46 149 8 0 1 1 1 0
9 82 7.44 20.2 9 1 1 1 0 0
10 70 7.42 127 9 1 1 1 1 1
11 75 9.05 436 9 0 1 1 1 0
12 49 9.00 121 9 1 1 1 1 1
13 64 7.47 1268 8 0 1 1 1 0
14 79 7.46 72.7 7b 0 0 1 0 0
15 73 9.04 19.6 9 1 0 1 1 0